Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Ahsan WahabAbdul RafaeMuhammad Salman FaisalKamran MushtaqHamid EhsanMaria KhakwaniAfia AshrafTayyab RehanZahoor AhmedZunairah ShahAslam KhanFaiz AnwarPublished in: Expert review of hematology (2020)
Maintenance strategy after ASCT has consistent PFS benefit but lacks conclusive OS improvement. Lenalidomide is superior to thalidomide given reduced neurotoxicity. OS advantage is controversial for both due to inconsistent evidence. Lenalidomide may confer a PFS advantage even at lower doses due to toxicity with higher doses. Bortezomib-based maintenance has some evidence for OS benefit in high-risk MM (HRMM) and renal dysfunction. Ixazomib has preliminary promising results. Two or three drug combinations for MT are potentially safe and more effective, particularly in HRMM although data on this subject is still evolving. Efficacy of various MT regimens in terms of minimal residual disease status needs to be further investigated.